According to Future Market Insights, the market for self-urinary infection testing is likely to project a compounded annual growth rate (CAGR) of 7.8% during the assessment period ranging from 2023 to 2033. As of 2023, a valuation of US$ 8.9 billion has been estimated for the market. This will eventually rise to US$ 18.86 billion in 2033.
Growth is expected to be fuelled by a rising prevalence of uncomplicated urinary tract infections and the subsequent need for self-testing kits, given their convenience and cost-effectiveness.
Urinary tract infections (UTIs) are the most common bacterial infection in the world, accounting for nearly 25% of all infections in women, and resulting in 250 million infections annually. Almost half of all women with a UTI will experience recurrent infections requiring additional antibiotic treatment. One out of three women will have to get antibiotic treatment for UTIs by the age of 24. The key culprit in this increase is an overdose of antibiotics in medicine and livestock.
As per a study conducted in 2019, incident cases of UTI, urolithiasis, and benign prostatic hyperplasia (BPH) increased by 60.48%, 48.57%, and 105.7% respectively from 1990. While the burden of urolithiasis and BPH has reduced considerably, UTI continues to pose a significant health risk to patients. Consequently, numerous therapeutic and treatment approaches have been developed in recent years. One of these approaches includes the detection of the disease before its progression, rendering the need for self-testing kits a necessity.
Timely and accurate identification and determination of the antimicrobial susceptibility of uropathogens is central to the management of UTIs. While urine dipsticks are amenable to point-of-care testing, they do not have adequate accuracy or provide a microbiological diagnosis.
Likewise, urine culture with antimicrobial susceptibility testing takes 2-3 days for results to be declared, and requires a laboratory setting. The use of antibiotics has led to an increase in multidrug-resistant organisms, thus ruling out its usage. Through the method of elimination, self-testing kits have emerged as the most convenient solution.
Self-urinary infection testing providers are leveraging technological advancements to the fullest in order to introduce top-of-the-line products. French consumer electronics company Withings introduced the U-Scan, a hockey-puck-shaped device that can be installed inside toilet bowls to analyse urine composition at the Consumer Electronics Show 2023, organized in January.
The company is initially releasing three cartridges. One is for women who want to track their menstrual cycles; the second provides more general health markers, such as fluid balance, protein-vegetable balance, and Vitamin C levels.
Inside the U-Scan is a replaceable cartridge, good for about three months, filled with dozens of test pods into which urine is injected. Chemical reactions then occur when one or several biomarkers are detected, producing specific colors that are analysed by an optical sensor.
The results of the U-Scan tests are shared over Wi-Fi to Withings private servers and made available through the company accompanying mobile apps, which allows the results and each user personal health data to be tracked over time.
Similarly, HealthyMe offers a urinary tract infection test kit comprising 3 individually-wrapped strips. The test is highly effective, providing results in just 2 minutes. The testing kit determines the presence of leukocytes and nitrites in urine. The future landscape is expected to be highly opportunistic, with many such product launches slated in the years to come.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value of Self-urinary Infection Testing in 2023 | US$ 8.9 billion |
| Projected Market Value of Self-urinary Infection Testing in 2033 | US$ 18.86 billion |
| Global Growth Rate (2023 to 2033) | CAGR of 7.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the latest research by Future Market Insights, Self-urinary infection testing market is set to witness a 7.8% growth during the year 2021 to 2031. The market is expected to witness growth owing to increasing prevalence of urinary tract infections and kidney diseases, surging volume of patients suffering from nephropathic disorders across the globe, increasing prevalence of geriatric population, changing lifestyle of the people.
A major factor boosting the growth of the market is the increasing prevalence of UTIs and nephropathic disorders. The lifestyle diseases like hypertension, diabetes, and obesity have an adverse effect on the excretion system, which includes the urinary tract, kidneys, lungs, skin and bladder. It affects the content of urine, appearance, and the concentration, hence leading to different nephropathic disorders.
Moreover, rise in the healthcare expenditure by the government initiatives promotes the affordability of devices, leading to growth sales of urinalysis products, boosting the growth of the market.
Furthermore, technological advancements in the field of self-diagnostics which is expected to boost the development of the market. For instance, in 2019, the federal FDA (Food and Drug Administration) approved a smartphone-based home urine test which allows patients with high-risk pregnancies, chronic diseases or urinary tract infections to observe their health by means of a testing method which is as easy as taking a smartphone selfie.
Principal Consultant
Self-urinary infection testing industry growth is projected to accelerate in the next five years, boosted by increasing prevalence of UTIs and nephropathic disorders which creates higher demand for different types of urine tests. The rising prevalence of UTIs and nephropathic diseases are caused by lifestyle diseases such as diabetes, hypertension, and obesity which makes an adverse effect on the excretion system, including bladder, urinary tract, and kidney.
A urinary screening program is suggested as an essential element for reducing the incidence of UTIs and kidney diseases which is anticipated to drive the demand for urinalysis test and boost the growth of Self-urinary infection testing market.
The USA Self-urinary infection testing market is expected to observe a robust growth in the market owing to high adoption of urinalysis for treatment of the urinary tract infections and liver disease, growth in research activities in the field of urinalysis and rising awareness among the people about urinalysis.
As per the National Diabetes Statics Report in 2017, approximately 30.3 million Americans (nearly 1 in 10) are affected with diabetes. Moreover, rising government initiatives for growing awareness of urinalysis among the people is a key factor boosting the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Europe would witness the highest growth after North America because of the rising prevalence of kidney diseases, rising per capita income resulting to better standard of living, rising healthcare spending, increasing demand for improved quality medical care, and rising awareness regarding urinalysis tests in Europe.
In addition, the rise in the incidence of nephropathic disorders and UTIs leads to the increasing demand for the diagnostic system, particularly self-diagnostic, because it is the most rapid growing segment of the diagnostic systems.
Some of the leading manufacturers and suppliers of Self-urinary infection testing include
The global Self-urinary infection testing market is slightly fragmented over the forecast years because of the presence of numerous testing device manufacturers who offer devices such as urinalysis test consumables and systems. Different Self-urinary infection testing device manufacturers are concentrated on developing novel technologies like dipsticks, recently approved mobile based home urine test.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Analysis and Forecast 6.1. Product 6.2. Application 6.3. End User 7. Global Analysis and Forecast, By Product 7.1. Dipsticks 7.2. Urine Assay Kit 7.3. Creatinine Urine Diagnostic Test Kit 7.4. Home Protein Urine Test Strips 8. Global Analysis and Forecast, By Application 8.1. Kidney Diseases 8.2. Urinary Tract Infections 8.3. Diabetes 8.4. Other Diseases 9. Global Analysis and Forecast, By End User 9.1. Diagnostic Laboratories 9.2. Hospitals & Clinics 9.3. Home Care Settings 9.4. Assisted Living Healthcare Facilities 9.5. Research Laboratories & Institutes 10. Global Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. South Asia 10.5. East Asia 10.6. Oceania 10.7. Middle East & Africa 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Europe Sales Analysis and Forecast, by Key Segments and Countries 14. South Asia Sales Analysis and Forecast, by Key Segments and Countries 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries 16. Oceania Sales Analysis and Forecast, by Key Segments and Countries 17. Middle East & Africa Sales Analysis and Forecast, by Key Segments and Countries 18. Sales Forecast by Product, Application, and End User for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Cardinal Health. 20.2. Abbott. 20.3. Siemens Healthcare Private Limited 20.4. F. Hoffmann-La Roche Ltd 20.5. Beckman Coulter, Inc. 20.6. Sysmex Middle East FZ-LLC 20.7. Quidel Corporation. 20.8. Bio-Rad Laboratories, Inc. 20.9. ARKRAY, Inc. 20.10. ACON Laboratories, Inc. 20.11. 77 Elektronika Kft 20.12. URIT MEDICAL ELECTRONIC Co., LTD. 20.13. Dirui. 20.14. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. 20.15. Healthy.io Ltd 20.16. Q Bio, Inc. 20.17. Scanwell Health, Inc. 20.18. Nova Biomedical 20.19. bioMérieux SA 20.20. Abaxis.
Healthcare
January 2023
REP-GB-16486
299 pages
Healthcare
November 2022
REP-GB-1451
250 pages
Explore Healthcare Insights
View Reports
Self-urinary Infection Testing Market
